Endokrynologia Polska · Published 2026-02-27 · DOI 10.5603/ep.110591
Hypoparathyroidism (HypoPT) remains the last “classic” endocrine deficiency hormone disorder not routinely treated with hormone replacement. In November 2023, European Medicines Agency (EMA), and in August 2024, Food and Drug Administration (FDA) registered a new parathyroid hormone analogue: palopegteryparatide (TransCon PTH; YORVIPATH®) for the treatment of selected cases of hypoparathyroidism. As the Polish Society of Endocrinology Expert Panel, we recommend that parathyroid hormone (PTH) replacement therapy should be considered for HypoPT patients in whom conventional therapy is insufficient or poorly tolerated. PTH replacement therapy offers a more physiologic approach to treating HypoPT than conventional therapy. Palopegteriparatide can lead to eucalcemia, more effectively than conventional treatment, lowers serum phosphate and urinary calcium, and improves renal function and quality of life.
Abstract from DOAJ. Public domain (CC0 1.0).
Read the article at the publisher →